Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
AAPS PharmSciTech ; 19(1): 232-241, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28681333

ABSTRACT

An aerosolized liposome formulation for the pulmonary delivery of an anti-asthmatic medication was developed. Asthma treatment usually requires frequent administration of medication for a sustained bronchodilator response. Liposomes are known for their sustained drug release capability and thus would be a suitable delivery system for prolonging the therapeutic effect of anti-asthmatic medication. Liposomes prepared by thin film hydration were loaded with a model drug, R-terbutaline hydrochloride(R-TBH), using an ammonium sulfate-induced transmembrane electrochemical gradient. This technique provided an encapsulation efficiency of up to 71.35% and yielded R-TBH liposomes with a particle size of approximately 145 ± 20 nm. According to stability studies, these R-TBH liposomes should be stored at 4°C before usage. Compared to R-TBH solution, which showed 90.84% release within 8 h, liposomal R-TBH had a cumulative release of 73.53% at 37°C over 192 h. A next generation impactor (NGI) was used to analyze the particle size distribution in the lungs of R-TBH liposome aerosol in vitro at 5°C. The therapeutic efficacy of the nebulized aerosol of the R-TBH liposomes was assessed via pulmonary delivery in guinea pigs. The results showed that, compared to the R-TBH solution group, the R-TBH liposome group had a prolonged anti-asthma effect.


Subject(s)
Bronchodilator Agents/administration & dosage , Terbutaline/administration & dosage , Administration, Inhalation , Aerosols , Animals , Bronchodilator Agents/chemistry , Bronchodilator Agents/therapeutic use , Delayed-Action Preparations , Drug Liberation , Guinea Pigs , Liposomes , Lung , Particle Size , Terbutaline/chemistry , Terbutaline/therapeutic use
2.
AAPS PharmSciTech ; 17(2): 380-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26169901

ABSTRACT

Laser diffraction (LD) and next generation impactor (NGI) are commonly used for the evaluation of inhaled drug formulations. In this study, the effect of temperature and humidity on the assessment of the nebulizer particle size distribution (PSD) by LD was investigated, and the consistency between NGI and LD measurements was evaluated. There was an increase in particle size with higher temperature or lower humidity. The particle population with a diameter less than 1 µm was significant at a temperature of 5°C or at relative humidity >90%; however, the same particle population became undetectable when temperature increased to 39°C or at relative humidity of 30-45%. The results of the NGI and LD measurements of aerosol generated from three types of jet nebulizers were compared. A poor correlation between the NGI and LD measurements was observed for PARI LC (2.2 µm) (R (2) = 0.893) and PARI LC (2.9 µm) (R (2) = 0.878), while a relatively good correlation (R (2) = 0.977) was observed for the largest particle size nebulizer (PARI TIA (8.6 µm)). We conclude that the ambient environment and the nebulizer have significant impacts on the performance and consistency between these instruments. These factors should be controlled in the evaluation of inhaled aerosol drug formulations when these instruments are used individually or in combination.


Subject(s)
Aerosols/chemistry , Chemistry, Pharmaceutical/methods , Humidity , Nebulizers and Vaporizers , Temperature , Lasers , Particle Size
SELECTION OF CITATIONS
SEARCH DETAIL
...